PANIXINE DISPERDOSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANIXINE DISPERDOSE (PANIXINE DISPERDOSE).
Panixine is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80% of elimination; biliary/fecal excretion accounts for 10-15%. |
| Half-life | 6-8 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in severe impairment). |
| Protein binding | 20% bound to serum albumin; low binding minimizes displacement interactions. |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Oral: 60-75% (first-pass metabolism reduces systemic exposure); Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; dose-dependent, with higher doses providing longer duration. |
Cefpodoxime proxetil (Panixine Disperdose) is administered orally (PO) as a dispersible tablet. Typical adult dose: 200 mg PO every 12 hours for 10-14 days for community-acquired pneumonia; 100 mg PO every 12 hours for 5-7 days for acute exacerbation of chronic bronchitis; 200 mg PO single dose for uncomplicated gonorrhea.
| Dosage form | TABLET, FOR SUSPENSION |
| Renal impairment | CrCl 30-49 mL/min: 200 mg PO every 24 hours. CrCl 10-29 mL/min: 200 mg PO every 24 hours (alternative recommendation: 100 mg every 24 hours based on some sources). CrCl <10 mL/min or hemodialysis: 200 mg PO every 24 hours, given after dialysis on dialysis days. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). No data for severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | For acute otitis media: 10 mg/kg/day PO divided every 12 hours for 5-10 days (max 400 mg/day). For pharyngitis/tonsillitis: 10 mg/kg/day PO divided every 12 hours for 5-10 days (max 200 mg/day). For sinusitis: 10 mg/kg/day PO divided every 12 hours for 10-14 days (max 400 mg/day). |
| Geriatric use | No specific adjustment based on age alone. Dose adjustment based on renal function as in adults. Monitor renal function (CrCl) and adjust dose accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PANIXINE DISPERDOSE (PANIXINE DISPERDOSE).
| Breastfeeding | Excreted in breast milk in low amounts (<10% of maternal dose). M/P ratio: 0.3 (for ibuprofen, the active ingredient). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no evidence of teratogenicity at therapeutic doses. Second and third trimesters: Use only if clearly needed; may cause premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to panixine, any cephalosporin, or any component of the formulation."]
| Precautions | ["Serious hypersensitivity reactions (including anaphylaxis) have been reported in patients with previous hypersensitivity to cephalosporins or penicillins.","Prolonged use may result in overgrowth of nonsusceptible organisms.","Use with caution in patients with renal impairment; dose adjustment required.","Clostridium difficile-associated diarrhea (CDAD) has been reported.","Seizures may occur with high doses or in patients with renal impairment."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function, blood pressure, and platelet count. In third trimester, ultrasound for amniotic fluid volume and ductus arteriosus patency if prolonged use. |
| Fertility Effects | Reversible inhibition of ovulation via prostaglandin synthesis interference; may delay conception but no permanent effect on fertility. |